Relmada Therapeutics (NASDAQ:RLMD) Coverage Initiated at Piper Sandler

Stock analysts at Piper Sandler initiated coverage on shares of Relmada Therapeutics (NASDAQ:RLMD) in a report released on Tuesday, MarketBeat.com reports. The brokerage set an “overweight” rating and a $12.00 price target on the stock. Piper Sandler’s price objective suggests a potential upside of 80.18% from the company’s current price.

Several other brokerages also recently commented on RLMD. Mizuho raised their price objective on Relmada Therapeutics from $10.00 to $19.00 and gave the stock an “outperform” rating in a research note on Friday, March 20th. Jefferies Financial Group assumed coverage on Relmada Therapeutics in a research note on Monday, December 22nd. They issued a “buy” rating and a $9.00 target price for the company. Leerink Partners upgraded Relmada Therapeutics from a “market perform” rating to an “outperform” rating and set a $8.00 price target for the company in a report on Friday, January 23rd. Lucid Cap Mkts raised Relmada Therapeutics to a “strong-buy” rating in a research report on Monday, March 2nd. Finally, Zacks Research upgraded Relmada Therapeutics to a “hold” rating in a report on Tuesday, January 27th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $12.00.

Relmada Therapeutics Stock Performance

RLMD opened at $6.66 on Tuesday. The firm’s fifty day moving average is $4.64 and its two-hundred day moving average is $3.68. The firm has a market cap of $488.38 million, a PE ratio of -4.59 and a beta of 0.72. Relmada Therapeutics has a twelve month low of $0.24 and a twelve month high of $7.51.

Relmada Therapeutics (NASDAQ:RLMD) last announced its quarterly earnings results on Thursday, March 19th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.13). Equities analysts forecast that Relmada Therapeutics will post -2.73 EPS for the current fiscal year.

Institutional Investors Weigh In On Relmada Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in RLMD. XTX Topco Ltd bought a new stake in Relmada Therapeutics in the 2nd quarter valued at $28,000. Goldman Sachs Group Inc. acquired a new position in Relmada Therapeutics in the 1st quarter worth $33,000. LMR Partners LLP bought a new position in Relmada Therapeutics during the 2nd quarter worth about $33,000. Schonfeld Strategic Advisors LLC bought a new position in Relmada Therapeutics during the 4th quarter worth about $64,000. Finally, Jane Street Group LLC bought a new position in Relmada Therapeutics during the 2nd quarter worth about $69,000. 45.24% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Relmada Therapeutics

Here are the key news stories impacting Relmada Therapeutics this week:

• Positive Sentiment: Piper Sandler initiated coverage with an “overweight” rating and a $12.00 price target (roughly +80% vs. the current price), giving institutional credibility to Relmada’s oncology program and signaling potential upside from clinical progress and re‑rating. Relmada wins bullish view at Piper Sandler
• Positive Sentiment: Mizuho published a bullish note on Relmada, reinforcing analyst interest and likely supporting near‑term buying given the firm’s focus on advancing therapeutics. Here’s What Makes Mizuho Bullish on Relmada
• Positive Sentiment: Brokerages’ consensus rating sits at “Moderate Buy,” reflecting broad analyst support that can attract momentum buyers and improve sentiment. Consensus Recommendation of “Moderate Buy”
• Neutral Sentiment: Multiple outlets report short‑interest data with conflicting figures — some automated reports show zero short interest (likely data errors), while others present nonzero levels. This inconsistency makes it hard to draw firm conclusions about short‑squeeze risk from the headlines alone. Short Interest Update
• Negative Sentiment: One report shows a large increase in short interest as of mid‑March — ~3.73M shares short (≈6.4% of float), a ~346% jump from late February — which could pressure the share price if negative news emerges or weigh on sentiment. (Conflicting data noted above.)
• Negative Sentiment: Recent quarterly results included an EPS miss (reported loss per share wider than consensus), reminding investors that pipeline execution and additional capital needs remain risks for a clinical‑stage biotech. This fundamental weakness can temper enthusiasm despite analyst upgrades.

About Relmada Therapeutics

Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada’s research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.

Relmada’s lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings.